Teleflex Incorporated

NYSE:TFX

Medical - Instruments & Supplies

Healthcare
$165.85 +0.83%

+$1.04 today

Market cap
$6.58B
Beta
0.82
P/E (TTM)
-5.5
EPS (TTM)
-$22.79
Dividend yield
1.08%
52W Low $100.18High $139.67

Volume 1.16M

Average 0.80M

TFX Income Tax Expense

Income taxes recognized for the period, including current and deferred tax.

Teleflex IncorporatedNYSE: TFX

Income Tax Expense · Q2 FY2026 · quarter ended Jun 2026

Income tax expense declines year over year

Q2 FY2026 income tax expense of $3.38M fell 73.3% year over year, ahead of the -161.0% change in trailing-twelve-month income tax expense. Sequentially, it rose 233.8% from the prior quarter.

Context

  • Income tax expense amounted to 1.7% of revenue in FY2025, up 1.5 pp from a year earlier.
  • Income tax expense increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -73.3% holds above the trailing-twelve-month pace of -161.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$3.38M+233.8% QoQ
Last fiscal yearDec 2025
-$33.98M-739.1% YoY
LTMJun 2026
-$34.18M-161.0% YoY
Income Tax Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-73.3%——
1 year-739.1%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Tax Expense history

USD · from the income statement

Latest · FY2025
(33.98M) USD
Year-over-year change
-739.1%

Income Tax Expense vs competitors

How TFX compares with its peers on the latest reported figures

  • Peers report in different currencies, so income tax expense is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -161.0% is the 8th highest of 10, against a peer median of -37.1%.
  • Income tax expense amounts to 1.3% of revenue for TFX, versus a peer median of 3.2%.
TFX Competitors
Income Tax Expense for TFX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BLCOBausch + Lomb CorporationLTM Jun 2026$98M USD+174.2%-15.5%1.8%
STVNStevanato Group S.p.A.LTM Jun 2026€57.41M EUR+27.3%+2.0%4.7%
MMSIMerit Medical Systems, Inc.LTM Sep 2026$51.59M USD+49.1%+73.6%3.2%
TGTXTG Therapeutics, Inc.LTM Sep 2026$43.49M USD+112.1%—4.8%
ALKSAlkermes plcLTM Sep 2026$11.66M USD-81.5%+190.8%0.7%
CRSPCRISPR Therapeutics AGLTM Sep 2026$2.34M USD-37.1%—9.3%
PCVXVaxcyte, Inc.LTM Jun 2026$0 USD———
ARWRArrowhead Pharmaceuticals, Inc.LTM Sep 2026-$6.78M USD-131.7%—1.5%
KRYSKrystal Biotech, Inc.LTM Jun 2026-$14.85M USD-167.4%—3.4%
PTCTPTC Therapeutics, Inc.LTM Jun 2026-$28.69M USD-177.7%—2.8%
TFXTeleflex IncorporatedLTM Jun 2026-$34.18M USD-161.0%—1.3%
Peer median (excluding TFX) —-37.1%+37.8%3.2%

Competitors are the stored peer set for TFX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.81B2.79B2.97B3.05B1.99B
Cost of Revenue1.26B1.26B1.33B1.34B871.96M
Gross Profit1.55B1.53B1.65B1.7B1.12B
Gross Margin55.2%54.9%55.4%55.9%56.2%
Research & Development130.84M153.82M154.35M161.67M144.78M
Selling, General & Admin860.09M863.75M929.87M995.27M720.17M
Operating Expenses921.51M1.03B1.14B1.55B864.95M
Depreciation & Amortization237.36M230.59M242.12M274.6M177.74M
EBITDA853.8M730.77M761.21M433.62M302.51M
EBITDA Margin30.4%26.2%25.6%14.2%15.2%
Operating Income628.1M499.73M506.31M151.01M255.8M
Operating Margin22.4%17.9%17.0%5.0%12.8%
Interest Income1.33M912K12.78M8.01M6.4M
Interest Expense56.97M54.26M85.08M83.54M100.22M
Other Income / Expenses(68.63M)(53.81M)(72.3M)(75.54M)(231.25M)
Income Before Tax559.47M445.92M434.01M75.48M24.55M
Pre-Tax Margin19.9%16.0%14.6%2.5%1.2%
Income Tax Expense74.35M83M76.44M5.32M(33.98M)
Net Income485.37M363.14M356.33M69.68M(905.64M)
Net Margin17.3%13.0%12.0%2.3%-45.4%
EPS (Basic)10.387.747.581.49(20.30)
EPS (Diluted)10.237.687.531.48(20.25)
Weighted Avg Shares46.77M46.9M46.98M46.84M44.62M
Weighted Avg Shares (Diluted)47.43M47.31M47.3M47.09M44.72M

Teleflex Incorporated

NYSE:TFX

Intrinsic Alpha fair value

Locked

Current Price

$165.85

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.